Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
MedinCell S.A. is a pharmaceutical company focused on the development of long-acting injectable therapeutics. Operating in the healthcare industry, MedinCell specializes in drug delivery technology that combines global health needs with the potential for improved patient adherence. The company is known for its proprietary BEPO technology, which allows for controlled and sustained release of medication. Founded in 2002 and headquartered in Jacou, France, the company works on a pipeline of therapeutic solutions across various segments, including pain management, contraception, and mental health. MedinCell's strategic position is reinforced by its collaborative partnerships and its innovative approach to addressing unmet medical needs with affordable healthcare solutions.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
MedinCell S.A.Johnson & Johnson
Last price
€28.30$276.22
Currency
EUR
USD
€1B$665B
-41.95
-€0.94$6.58
0.910.21
0$5.28
01.94%
Sector
HealthHealth
Employees
141138,200
Ticker
€MEDCL$JNJ
Primary listing
PARNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €MEDCL or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.